Highly statistically significant improvement in pruritus primary endpoint (p=0.002)
Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001)
Substantial improvements in multiple sleep parameters
Well tolerated with low incidence of drug-related diarrhea, no discontinuations
Plans to immediately file in the U.S. and EU, adding to approved indication for PFIC
Conference call to be held today at 8:30am EDT
Albireo will host a conference call and live audio webcast at 8:30 a.m. EDT. To access the live conference call by phone, dial 1-877-407-0792 (domestic) or 1-201-689-8263 (international), and provide the access code 13733685. A live audio webcast will be accessible from the Investors page at ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that participants register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for 3 months following the event.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.